|
Nordic Bio Investor portfolio performance
The NBI Investment Portfolio was launched on March 25th, 2011.
We publicly disclose the performance of the portfolio by the end of each quarter. Please note that only our clients have access to the specific stocks and their relative weigthting in the portfolio.
The NBI investment portfolio consists of public listed Nordic Life Sciences companies in Denmark, Finland, Norway and Sweden.
Accumulated return since portfolio inception by 25 March 2011:
Performance listed as of March 31st, 2013
NBI Investment Portfolio: +22.8%
Primary Peer - Nordic Life Science Index: -1.5%
Secondary Peer - EuroNext Biotech Index: +16.9%
Annual performance for present and previous years:
2013 year to date (last update: March 31st, 2013)
NBI Investment Portfolio: +33.3%
Primary Peer - Nordic Life Science Index: +16.3%
Secondary Peer - EuroNext Biotech Index: -0.7%
2012
NBI Investment Portfolio: +3.9%
Primary Peer - Nordic Life Science Index: -2.5%
Secondary Peer - EuroNext Biotech Index: +26.6%
2011
NBI Investment Portfolio: -11.3%
Primary Peer - Nordic Life Science Index: -23.8%
Secondary Peer - EuroNext Biotech Index: -29.8%
|
 |
Become a Client/Subscriber
For new Corporate Clients we are right now offering a free 6-week no commitment trial period which include 3 issues of NBI Insight.
For new Individual Clients we are offering a free 2-week no commitment trial period, which include 1 issue of NBI Insight.
To sign up for a free trial period please fill in the requested information below:
|
